These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor. Gurbel PA Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887 [TBL] [Abstract][Full Text] [Related]
5. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW Thromb Haemost; 2009 Feb; 101(2):333-9. PubMed ID: 19190818 [TBL] [Abstract][Full Text] [Related]
6. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. Patti G; Nusca A; Mangiacapra F; Gatto L; D'Ambrosio A; Di Sciascio G J Am Coll Cardiol; 2008 Sep; 52(14):1128-33. PubMed ID: 18804738 [TBL] [Abstract][Full Text] [Related]
7. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. Motovska Z; Kala P Clin Ther; 2008; 30 Pt 2():2191-202. PubMed ID: 19281914 [TBL] [Abstract][Full Text] [Related]